Treatment of oropharyngeal squamous cell carcinoma with IMRT: Patterns of failure after concurrent chemoradiotherapy and sequential therapy

Annals of Oncology

Volumn 23, Issue 9, 2012, Pages 2391-2398

  Sher, D J ^a   Thotakura, V ^a,b   Balboni, T A ^a   Norris, C M ^a   Haddad, R I ^a,b   Posner, M R ^c   Lorch, J ^a,b   Goguen, L A ^a   Annino, D J ^a   Tishler, R B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Combined modality therapy; Head and neck cancer; Human papillomavirus; Imrt; Oropharynx cancer; Sequential therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; DRUG EFFECT; EDEMA; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING;

AGED; ALBUMINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMAN PAPILLOMAVIRUS 16; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PACLITAXEL; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; RADIATION TOLERANCE; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT FAILURE;

EID: 84865548695     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr609     Document Type: Article

References (19)

1. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76. Published on 20031202.
2. Eisbruch A. Reducing xerostomia by IMRT: what may, and may not, be achieved. J Clin Oncol 2007; 25: 4863-4864.
3. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35. Published on 20100607.
4. Chen AM, Farwell DG, Luu Q et al. Marginal misses after postoperative intensitymodulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1423-1429. Published on 20100723.
5. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 70: 660-665. Published on 20071126.
6. Setton J, Caria N, Romanyshyn J et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 2010; 82(1) 291-298.
7. Daly ME, Le QT, Maxim PG et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010; 76: 1339-1346. Published on 20090618.
8. Huang K, Xia P, Chuang C et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 2008; 113: 497-507.
9. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
10. Beitler JJ, Cooper JS. Seduction by induction?. J Clin Oncol 2009; 27: 9-10. Published on 20081201.
11. Kies MS, Holsinger FC, Lee JJ et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14. Published on 20091116.
12. Salama JK, Haddad RI, Kies MS et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009; 75: 725-733. Published on 20090411.
13. Popovtzer A, Gluck I, Chepeha DB et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009; 74: 1342-1347. Published on 20090108.
14. Gelman R, Gelber R, Henderson IC et al. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990; 8: 548-555.
15. Coca-Perraillon M. Local and Global Optimal Propensity Score Matching. NorthEast SAS Users Group Conference (NESUG), Philadelphia, USA. 2006. (16 February 2012, date last accessed).
16. Mouw KW, Haraf DJ, Stenson KM et al. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2010; 136: 1226-1234.
17. van Herpen CM, Mauer ME, Mesia R et al. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 2010; 103: 1173-1181. Published on 20100914.
18. Kuo YC, Wu TH, Chung TS et al. Effect of regression of enlarged neck lymph nodes on radiation doses received by parotid glands during intensitymodulated radiotherapy for head and neck cancer. Am J Clin Oncol 2006; 29: 600-605.
19. Hansen EK, Bucci MK, Quivey JM et al. Repeat CT imaging and replanning during the course of IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 64: 355-362. Published on 20051026